INmune Bio Plunges 44.47% on Share Offering Concerns

On June 30, 2025, INmune Bio experienced a significant drop of 44.47% in pre-market trading, sparking concerns among investors and analysts alike.

INmune Bio's stock price has been under pressure due to a recent announcement of a 3 million share offering. This move, aimed at raising capital for ongoing clinical trials, has raised concerns among investors about the company's financial health and future prospects. The offering comes ahead of mid-stage trial data, which is crucial for the company's pipeline and investor confidence.

Despite the recent setback, retail investors have shown resilience and continued support for INmune Bio. The company's innovative approach to immunotherapy and its promising pipeline have garnered a loyal following among retail traders, who remain optimistic about its long-term potential. This retail support has been a stabilizing factor amidst the volatility caused by the share offering.

INmune Bio's stock performance reflects the broader market sentiment towards biotech companies, which are often subject to significant fluctuations based on clinical trial outcomes and regulatory developments. The company's ability to navigate these challenges and deliver positive trial results will be critical in determining its future trajectory.